Table 1 Descriptive demographic, radiochemical, and clinical data for patients and healthy control subjects.

From: Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis

 

Controls

Patients

Mean (SD)

Min–max

Mean (SD)

Min–max

p

Age (years)

29.2 (5.9)

20–43

29.3 (6.3)

18–42

0.75

Body mass index (kg/m2)

24.7 (3.1) (N = 16)

18.5–30

23.5 (2.4)

20–31

0.33

Education (years)

15.2 (2.2) (N = 17)

12–20

15.2 (3.3) (N = 17)

10–22

0.77

Injected activity (MBq)

431.4 (47.1)

317–480

420.5 (49.5)

292–480

0.48

Molar Mass (GBq/mmol)

285.5 (125.3)

122–543

462.1 (228.6)

117–955

0.01

Injected mass (microg)

0.7 (0.4)

0.27–1.31

0.4 (0.2)

0.17–0.93

0.01

Cerebellum SUV total

6315 (1924)

3290–9974

5830 (2227)

2569–10297

0.35

Cerebellum SUV 25–85 min

55 (17)

30–80

51 (20)

22–96

0.37

Duration of illness (months)

  

12.1 (19.5)

1–84

 

CGI

  

4.5 (1.0)

3–6

 

PANSS-total

  

65.6 (17.4)

39–97

 

PANSS-global

  

33.6 (9.7)

18–54

 

PANSS-positive

  

17.7 (4.2)

11–24

 

PANSS-negative

  

14.4 (6.2)

7–28

 
  1. SUV Standardized uptake values, CGI Clinical Global Impressions Scale, PANSS Positive and Negative Syndrome Scale.
Back to article page